GH1 and metabolic dysfunction-associated steatotic liver disease: In HIV-associated MASLD, the growth hormone (GH)-releasing hormone analog tesamorelin reduced liver fat and prevented fibrosis progression while down-modulating hepatic gene sets involved in inflammation and tissue repair, providing mechanistic plausibility that IGF-axis modulators can shift the milieu in which IGFBP-6 operates [74,75].